Novo rival faces massive challenges
US pharma giant, Eli Lilly, is racing the clock. Within the next year, three of the company’s drugs, accounting for 40 % of turnover, are set to go off patent. Looking ahead to 2017, the patent expirations are even greater, covering 63 % of turnover. Too broad a focus and stricter regulatory requirements are to blame.
by Stefan Singh Kailay
Zyprexa has already fallen victim to the cold grasp of the generics industry. Within the next year, the same will happen to Cymbalta, Evista and Humalog, while another three drugs go off patent by 2017.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Novo Nordisk silent about the loss of massive contract
For abonnenter
Analyst: The stage is set for diabetes showdown
For abonnenter
Eli Lilly presents new data on Victoza challenger
For abonnenter
.jpg&w=384&q=75)
